Advertisement

Journal of Urban Health

, Volume 82, Issue 3, pp 411–419 | Cite as

Attitudes and practices regarding the use of methadone in US State and federal prisons

  • Josiah D. RichEmail author
  • Amy E. Boutwell
  • David C. Shield
  • R. Garrett Key
  • Michelle McKenzie
  • Jennifer G. Clarke
  • Peter D. Friedmann
Article

Abstract

In the United States, vigorous enforcement of drug laws and stricter sentencing guidelines over the past 20 years have contributed to an expanded incarcerted population with a high rate of drug use. One in five state prisoners reports a history of injection drug use, and many are opiate dependent. For over 35 years, methadone maintenance therapy has been an effective treatment for opiate dependence; however, its use among opiate-dependent inmates in the United States is limited. In June 2003, we conducted a survey of the medical directors of all 50 US states and the federal prison system to describe their attitudes and practices regarding methadone. Of the 40 respondents, having jurisdiction over 88% (n=1,266,759) of US prisoners, 48% use methadone, predominately for pregnant inmates or for short-term detoxification. Only 8% of respondents refer opiate-dependent inmates to methadone programs upon release. The results highlight the need to destigmatize the use of methadone in the incarcerated setting, expand access to methadone during incarceration, and to improve linkage to methadone treatment for opiate-dependent offenders who return to the community.

Keywords

Hepatitis B Hepatitis C HIV Incarceration Methadone Opiate dependence Overdose Prison Prisoners Recidivism 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bureau of Justice Statistics. Corrections statistics: summary findings. Available at: http:// www.ojp.usdoj.gov/bjs/correct.htm. Accessed May 4, 2005.Google Scholar
  2. 2.
    Federal Bureau of Investigation. Uniform crime reports: crime in the United States. Available at: http://www.fbi.gov/ucr/ucr.htm. Accessed May 4, 2005.Google Scholar
  3. 3.
    Drucker E. Drug prohibition and public health: 25 years of evidence. Public Health Rep. 1999;114:14–29.CrossRefPubMedGoogle Scholar
  4. 4.
    Center for Disease Control and Prevention. Drug use, HIV, and the criminal justice system. IDU HIV Prevention, 2001. Available at: http://www.cdc.gov/idu/facts/criminaljusticefactsheet. pdf. Accessed May 4, 2005.Google Scholar
  5. 5.
    Califano JA. Behind Bars: Substance Abuse and America’s Prison Population. Population, CASA Report. New York, New York. National Center on Addiction and Substance Abuse at Columbia University; 1998.Google Scholar
  6. 6.
    Bureau of Justice Statistics. Substance abuse and treatment of state and federal prisoners, 1999. Available at: http://www.ojp.usdoj.gov/bjs/abstract/satsfp97.htm. Accessed May 4, 2005.Google Scholar
  7. 7.
    Hammett TD, Harmon MP, Rhodes W. The burden of infectious disease among inmates of and releases from US correctional facilities. Am J Public Health. 2002;92:1789–1794.PubMedGoogle Scholar
  8. 8.
    Spaulding A, Greene C, Davidson K, Schneidermann M, Rich JD. Hepatitis C in state correctional facilities. Prev Med. 1999;28:92–100.CrossRefPubMedGoogle Scholar
  9. 9.
    Reindollar RW. Hepatitis C and the correctional population. Am J Med. 1999;107:100S-103S.CrossRefPubMedGoogle Scholar
  10. 10.
    Centers for Disease Control and Prevention (CDC). Prevention and control of infections with hepatitis viruses in correctional settings. MM WR Morb Mortal Wkly Rep. 2003; 52:1–36.Google Scholar
  11. 11.
    Rapposelli KK, Kennedy MG, Miles JR, et al. HIV/AIDS in correctional settings: a salient priority for the CDC and HRSA. AIDS Educ Prev. 2002;14:103–113.CrossRefPubMedGoogle Scholar
  12. 12.
    Nurco DN, Hanlon TE, Kinlock TW. Recent research on the relationship between illicit drug use and crime. Behav Sci Law. 1991;9:221–242.Google Scholar
  13. 13.
    Nurco DN, Stephenson PE, Hanlon TE. Affercare/relapse prevention and the self-help movement. Addiction. 1991;25:1179–1200.Google Scholar
  14. 14.
    Hanlon TE, Nurco DN, Kinlock TW, Duszynski KR. Trends in criminal activity and drug use over an addiction career. Am J Drug Alcohol Abuse. 1990;16:223–238.PubMedGoogle Scholar
  15. 15.
    Inciardi JA, McBride D, Suratt H. The heroin street addict: profiling a national population. In: Inciardi JA, Harrison LD, eds. Heroin in the Age of Crack-Cocaine. Thousand Oaks, CA: Sage; 1998:31–50.Google Scholar
  16. 16.
    Seaman SR, Brettle RP, Gore SM. Mortality from overdose among injecting drug users recently released from prison: database linkage study. BMJ. 1998;316:426–428.PubMedGoogle Scholar
  17. 17.
    Bird SM, Hutchinson SJ. Male drug-related deaths in the fortnight after release from prison: Scotland. Addiction. 2003;98:185–190.CrossRefPubMedGoogle Scholar
  18. 18.
    Singleton N, Taylor C, Farrell M, Marsden J. Drug-Related Mortality Among Newly Released Offenders. London: Communications Development Unit, Home Office; 2003.Google Scholar
  19. 19.
    Weatherburn D, Lind B. Heroin harm minimisation: do we really have to choose between law enforcement and treatment? Crime Justice Bull. 1999;46:1–11.Google Scholar
  20. 20.
    Seal KH, Kral AH, Gee L, et al. Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay Area. Am J Public Health. 2001;91:1842–1846.PubMedGoogle Scholar
  21. 21.
    Merrill J, Alterman A, Cacciola J, Rutherford M. Prior treatment history and its impact on criminal recidivism. J Subst Abuse Treat. 1999;17:313–319.CrossRefPubMedGoogle Scholar
  22. 22.
    Dole V, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. N Engl J Med. 1969;280:1372–1375.PubMedCrossRefGoogle Scholar
  23. 23.
    McGlothlin WH, Anglin MD, Wilson BD. Outcome of the California civil addict commitments. Drug Alcohol Depend. 1976;1:165–181.CrossRefPubMedGoogle Scholar
  24. 24.
    McLellan AT, Arndt IO, Metzger DS, et al. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269:1953–1959.CrossRefPubMedGoogle Scholar
  25. 25.
    Magura S, Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med. 2001;68:62–74.PubMedGoogle Scholar
  26. 26.
    Sees K, Delucci K, Masson C, et al. Methadone maintenance vs. 180-day psychologically enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283:1303–1310.CrossRefPubMedGoogle Scholar
  27. 27.
    Nestler EJ, Aghanajanian GK. Molecular and cellular basis of addiction. Science. 1997;278:58–63.CrossRefPubMedGoogle Scholar
  28. 28.
    Ward J, Mattick RP, Hall W, eds. Methadone Maintenance Treatment and Other Opioid Replacement Therapies. Australia: Harwood Academic Publishers; 1998.Google Scholar
  29. 29.
    Metzger D, Navaline H, Woody G. Drug abuse treatment as AIDS prevention. Public Health Rep. 1998;133:97–106.Google Scholar
  30. 30.
    Capelhom JRM, Ross MW. Methadone maintenance and the likelihood of risky needlesharing. Addiction. 1995;30:685–698.Google Scholar
  31. 31.
    Newman RG, Bashkow S, Cates M. Arrest histories before and after admission to methadone. Contemp Drug Probl. 1973:417–430.Google Scholar
  32. 32.
    Center for Disease Control and Prevention. Substance abuse treatment for drug users in the cirminal justice system. IDU HIV Prevention, 2002. Available at: http:// www.cdc.gov/idu/facts/TreatmentFin.pdf. Accessed May 4, 2005.Google Scholar
  33. 33.
    Martin SS, Butzin CA, Saum CA, Inciardi JA. Three-year outcomes of therapeutic community treatment for drug-involved offenders in Delaware: from prison to work release to aftercare. Prison J. 1999;79:294–320.CrossRefGoogle Scholar
  34. 34.
    Center for Disease Control and Prevention. Helping inmates return to the community. IDU HIV prevention, 2001. Available at: http://www.cdc.gov/idu/facts/cj-transition.pdf. Accessed May 4, 2005.Google Scholar
  35. 35.
    Grinstead O, Zack B, Faigeles B. Reducing post release risk behavior among HIV seropositive inmates: the health promotion program. AIDS Educ Prev. 2001;13:109–119.CrossRefPubMedGoogle Scholar
  36. 36.
    Travis J, Solomon AL, Waul M. From prison to home: the dimensions and consequences of prison reentry. Urban Health Institute, 2001. Available at: http://www.urban.org/ pdfs/from_prison_to_home.pdf. Accessed May 4, 2005.Google Scholar
  37. 37.
    Dolan K, Wodak A. An international review of methadone provision in prisons. Addict Res. 1996;4:85–97.Google Scholar
  38. 38.
    Sibbald B. Methadone maintenance expands inside federal prisons. CMAJ. 2002; 167:1154.PubMedGoogle Scholar
  39. 39.
    Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend. 2003;72:59–65.CrossRefPubMedGoogle Scholar
  40. 40.
    Fallon BM. The Key Extended Entry Program (KEEP): from the community side of the bridge. Mt Sinai J Med. 2001;68:21–27.PubMedGoogle Scholar
  41. 41.
    Tomasino V, Swanson AJ, Nolan J, Shuman HI. The Key Extended Entry Program (KEEP): a metha done treatment program for opiate-dependent inmates. Mt Sinai J Med. 2001;68:14–20.PubMedGoogle Scholar
  42. 42.
    Gerra G, Ferri M, Polidori E, Santoro G, Zaimovic A, Sternieri E. Long-term methadone maintenance effectiveness: psychosocial and pharmacological variables. J Subst Abuse Treat. 2003;25:1–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Office of National Drug Control Policy. Consultation Document on Methadone/LAAM. Washington, DC: ONDCP; 1998.Google Scholar
  44. 44.
    Warren E, Viney R. CHERE: an economic evaluation of the prison methadone program in New South Wales, 2004: Available at: http://www.chere.uts.edu.au/pdf/rep22.pdf. Accessed May 4, 2005.Google Scholar
  45. 45.
    Clarke JG, Stein MD, Hanna L, Sobota M, Rich JD. Active and former IDU report of HIV risk behaviors during periods of incarceration. Subst Abuse. 2001;22:209–216.CrossRefGoogle Scholar
  46. 46.
    Calzavara LM, Burchell AN, Schlossberg J, et al. Prior opiate injection and incarceration history predict injection drug use among inmates. Addiction. 2003;98:1257–1265.CrossRefPubMedGoogle Scholar
  47. 47.
    Koulierakis G, Gnardellis C, Agrafiotis D, Power KG. HIV risk behaviour correlates among injecting drug users in Greek prisons. Addiction. 2000;95:1207–1216.CrossRefPubMedGoogle Scholar
  48. 48.
    Champion JK, Taylor A, Hutchinson S, et al. Incidence of hepatitis C virus infection and associated risk factors among Scottish prison inmates: a cohort study. Am J Epidemiol. 2004;159:514–519.CrossRefPubMedGoogle Scholar
  49. 49.
    Macalino GE, Vlahov D, Sandford S, et al. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health. 2004;4:1218–1223.CrossRefGoogle Scholar
  50. 50.
    Magura S, Rosenblum A, Joseph H. Evaluation of in-jail methadone maintenance: preliminary results. NIDA Research Monograph. 1992;118:192–210.PubMedGoogle Scholar
  51. 51.
    Rich JD, McKenzie M, Carleton JC, Rizzi MA, Wolf FA, Crosland C. Linkage to methadone upon release from incarceration: a model. Paper presented at: APHA 131 st Annual Meeting; November 19, 2003; San Francisco.Google Scholar
  52. 52.
    United States Code of Federal Regulations Certification of Opioid Treatment Programs, 42 CFR §8, 2005. Available at: http://dpt.samhsa.gov/otp.htm. Accessed May 4, 2005.Google Scholar

Copyright information

© Oxford University Press on behalf of the New York Academy of Medicine 2005

Authors and Affiliations

  • Josiah D. Rich
    • 1
    Email author
  • Amy E. Boutwell
    • 1
  • David C. Shield
    • 1
  • R. Garrett Key
    • 2
  • Michelle McKenzie
    • 1
  • Jennifer G. Clarke
    • 3
  • Peter D. Friedmann
    • 3
  1. 1.The Miriam Hospital/Brown Medical SchoolProvidence
  2. 2.Texas Tech UniversityLubbock
  3. 3.Rhode Island HospitalProvidence

Personalised recommendations